Aspire Biopharma Holdings, Inc. (ASBP) Financial Ratios
3 years of historical data (2022–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
↓
N/A
—
5yr avg: -0.2%
30Y Low-0%·High-0%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ASBP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aspire Biopharma Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Market Cap | $7M | — | — | — |
| Enterprise Value | $9M | — | — | — |
| P/E Ratio → | -0.60 | — | — | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | — | — | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ASBP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
ASBP Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ROE | — | — | -0.2% | -0.2% |
| ROA | -12914.4% | -12914.4% | -0.2% | -0.2% |
| ROIC | — | — | -0.2% | -0.2% |
| ROCE | — | — | -0.2% | -0.2% |
ASBP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $1M ($1M total debt minus $3633 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Debt / Equity | — | — | — | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | — | — | -0.00 |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | -3.46 | -3.46 | -39.99 | — |
ASBP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.09x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 3.62x to 0.09x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Current Ratio | 0.09 | 0.09 | 0.09 | 3.62 |
| Quick Ratio | 0.09 | 0.09 | 0.09 | 3.62 |
| Cash Ratio | 0.00 | 0.00 | 0.02 | 1.64 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
ASBP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aspire Biopharma Holdings, Inc. returns 100.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 100.0% | — | — | — |
| Total Shareholder Yield | 100.0% | — | — | — |
| Shares Outstanding | — | $48M | $46M | $46M |
Peer Comparison
Compare ASBP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ASBPYou | $7M | -0.6 | — | — | — | — | — | — | — |
 CRBP | $136M | -1.8 | — | — | — | — | -54.2% | -51.4% | — |
 YCBD | $8M | -0.8 | — | — | 56.5% | -11.3% | -44.4% | -0.4% | — |
 XXII | $118791 | -0.0 | — | — | -20.2% | -64.9% | -51.1% | -81.4% | — |
 ATAI | $964M | -4.3 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 CMPS | $902M | -3.0 | — | — | — | — | -565.3% | — | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 CRON | $981M | — | — | — | 32.5% | -1.5% | -0.9% | -0.8% | — |
 CGC | $122M | -0.3 | — | — | 29.6% | -43.5% | -121.1% | -10.2% | — |
 TLRY | $660M | -0.2 | — | — | 29.3% | -277.9% | -89.1% | -66.2% | — |
 ACB | $195M | 164.4 | 6.7 | — | 54.6% | 1.4% | 0.3% | 0.7% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 3 years · Updated daily
See ASBP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ASBP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ASBP vs CRBP
Side-by-side business, growth, and profitability comparison vs Corbus Pharmaceuticals Holdings, Inc..
Start ComparisonASBP — Frequently Asked Questions
Quick answers to the most common questions about buying ASBP stock.
What is Aspire Biopharma Holdings, Inc.'s P/E ratio?
Aspire Biopharma Holdings, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
Is ASBP stock overvalued?
Based on historical data, Aspire Biopharma Holdings, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.